IL-6 is required for glioma development in a mouse model
- PMID: 15064729
- DOI: 10.1038/sj.onc.1207455
IL-6 is required for glioma development in a mouse model
Abstract
The pleiotropic cytokine interleukin-6 (IL-6) contributes to malignant progression and apoptosis resistance of various cancer types. Although IL-6 is elevated in malignant gliomas, and glioma cells respond to IL-6, its functional role in gliomagenesis is unclear. We have investigated this role of IL-6 in a mouse model of spontaneous astrocytoma by crossbreeding glial fibrillary acidic protein (GFAP)-viral src oncogene transgenic mice with IL-6-deficient mice. We show here that ablation of IL-6 prevents tumour formation in these predisposed animals, but did not affect preneoplastic astrogliosis. Moreover, we demonstrate phosphorylation and nuclear translocation of the transcription factor signal transducer and activator of transcription (STAT)3, a prerequisite for IL-6 signalling, in 51 human gliomas WHO grade II-IV and all experimental mouse tumours investigated. Together with the observation that STAT3 activation increases with malignancy, these findings indicate an important role for IL-6 in the development and malignant progression of astrocytomas.
Copyright 2004 Nature Publishing Group
Similar articles
-
Interleukin-6 is required for the early induction of glial fibrillary acidic protein in Schwann cells during Wallerian degeneration.J Neurochem. 2009 Feb;108(3):776-86. doi: 10.1111/j.1471-4159.2008.05826.x. J Neurochem. 2009. PMID: 19187095
-
Interleukin-6 gene ablation in a transgenic mouse model of malignant skin melanoma.Am J Pathol. 2005 Mar;166(3):831-41. doi: 10.1016/S0002-9440(10)62304-8. Am J Pathol. 2005. PMID: 15743795 Free PMC article.
-
Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model.Cancer Res. 2003 Mar 1;63(5):1106-13. Cancer Res. 2003. PMID: 12615729
-
Transgenic models to assess the neuropathogenic potential of HIV-1 proteins and cytokines.Curr Top Microbiol Immunol. 1995;202:187-205. doi: 10.1007/978-3-642-79657-9_13. Curr Top Microbiol Immunol. 1995. PMID: 7587363 Review. No abstract available.
-
[Neurobiological effect of interleukin-6].Sheng Li Ke Xue Jin Zhan. 1995 Jan;26(1):57-60. Sheng Li Ke Xue Jin Zhan. 1995. PMID: 7604225 Review. Chinese. No abstract available.
Cited by
-
Regulation and dysregulation of astrocyte activation and implications in tumor formation.Cell Mol Life Sci. 2013 Nov;70(22):4201-11. doi: 10.1007/s00018-013-1274-8. Epub 2013 Feb 19. Cell Mol Life Sci. 2013. PMID: 23420481 Free PMC article. Review.
-
IL-6 is associated with poor seizure control in low-grade glioma patients undergoing primary resection.iScience. 2024 Jun 13;27(7):110267. doi: 10.1016/j.isci.2024.110267. eCollection 2024 Jul 19. iScience. 2024. PMID: 39021786 Free PMC article.
-
Antitumor activity of novel pyrazole-based small molecular inhibitors of the STAT3 pathway in patient derived high grade glioma cells.PLoS One. 2019 Jul 30;14(7):e0220569. doi: 10.1371/journal.pone.0220569. eCollection 2019. PLoS One. 2019. PMID: 31361777 Free PMC article.
-
Colony‑stimulating factor CSF2 mediates the phenotypic plasticity of small‑cell lung cancer by regulating the p‑STAT3/MYC pathway.Oncol Rep. 2022 Jul;48(1):122. doi: 10.3892/or.2022.8333. Epub 2022 May 18. Oncol Rep. 2022. PMID: 35583004 Free PMC article.
-
Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice.Mol Ther Oncolytics. 2023 Aug 15;30:238-253. doi: 10.1016/j.omto.2023.08.004. eCollection 2023 Sep 21. Mol Ther Oncolytics. 2023. PMID: 37701849 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous